Table 1.
Description of the three NAPKON sub-cohorts in the original and anonymized (PUF) dataset from 2022-03-15.
| Original (n = 4,562) | Anonymized (n = 3,904) | |||||
|---|---|---|---|---|---|---|
| SUEP (n = 1,697) | POP (n = 2,346) | HAP (n = 519) | SUEP (n = 1,387) | POP (n = 2,280) | HAP (n = 237) | |
| Age in years | ||||||
| <18 | 40 (2.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| 18–39 | 317 (18.7%) | 920 (39.2%) | 78 (15.0%) | 275 (19.8%) | 917 (40.2%) | 0 (0%) |
| 40–59 | 609 (35.9%) | 967 (41.2%) | 230 (44.3%) | 541 (39.0%) | 957 (42.0%) | 129 (54.4%) |
| 60–79 | 584 (34.4%) | 412 (17.6%) | 187 (36.0%) | 528 (38.1%) | 394 (17.3%) | 108 (45.6%) |
| >79 | 147 (8.7%) | 35 (1.5%) | 23 (4.4%) | 43 (3.1%) | 12 (0.5%) | 0 (0%) |
| Missing | 0 (0%) | 12 (0.5%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gender | ||||||
| Male | 1,020 (60.1%) | 1,040 (44.3%) | 352 (67.8%) | 868 (62.6%) | 1001 (43.9%) | 181 (76.4%) |
| Female | 677 (39.9%) | 1,305 (55.6%) | 166 (32.0%) | 519 (37.4%) | 1,279 (56.1%) | 56 (23.6%) |
| Missing | 0 (0%) | 1 (0.04%) | 1 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Quarter and year of first COVID-19 diagnosis | ||||||
| Q1 2020 | 2 (0.1%) | 554 (23.6%) | 11 (2.1%) | 0 (0%) | 541 (23.7%) | 0 (0%) |
| Q2 2020 | 0 (0%) | 279 (11.9%) | 24 (4.6%) | 0 (0%) | 271 (11.9%) | 0 (0%) |
| Q3 2020 | 7 (0.4%) | 275 (11.7%) | 19 (3.7%) | 0 (0%) | 265 (11.6%) | 0 (0%) |
| Q4 2020 | 68 (4.0%) | 748 (31.9%) | 61 (11.8%) | 0 (0%) | 740 (32.4%) | 0 (0%) |
| Q1 2021 | 534 (31.5%) | 367 (15.6%) | 156 (30.1%) | 496 (35.8%) | 365 (16.0%) | 130 (54.9%) |
| Q2 2021 | 397 (23.4%) | 86 (3.7%) | 108 (20.8%) | 390 (28.1%) | 76 (3.3%) | 85 (35.9%) |
| Q3 2021 | 208 (12.3%) | 1 (0.04%) | 39 (7.5%) | 194 (14.0%) | 0 (0%) | 0 (0%) |
| Q4 2021 | 357 (21.0%) | 1 (0.04%) | 72 (13.9%) | 307 (22.1%) | 0 (0%) | 22 (9.3%) |
| Q1 2022 | 66 (3.9%) | 0 (0%) | 7 (1.3%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Missing | 58 (3.4%) | 35 (1.5%) | 22 (4.2%) | 0 (0%) | 22 (1.0%) | 0 (0%) |
| WHO Clinical Progression Scale most severe phase | ||||||
| Mild | 191 (11.3%) | 2185 (93.1%) | 0 (0%) | 149 (10.7%) | 2131 (93.5%) | 0 (0%) |
| Moderate | 1,135 (66.9%) | 124 (5.3%) | 320 (61.7%) | 919 (66.3%) | 114 (5.0%) | 144 (60.8%) |
| Severe | 349 (20.6%) | 37 (1.6%) | 199 (38.3%) | 307 (22.1%) | 35 (1.5%) | 93 (39.2%) |
| Missing | 22 (1.3%) | 0 (0%) | 0 (0%) | 12 (0.9%) | 0 (0%) | 0 (0%) |
| Patient status at end acute phase | ||||||
| Ambulant | 192 (11.3%) | 2,108 (89.9%) | 0 (0%) | 149 (10.7%) | 2,069 (90.7%) | 0 (0%) |
| Discharged | 1,084 (63.9%) | 124 (5.3%) | 407 (78.4%) | 911 (65.7%) | 112 (4.9%) | 180 (75.9%) |
| Referral/transfer | 221 (13.0%) | 0 (0%) | 26 (5.0%) | 176 (12.7%) | 0 (0%) | 14 (5.9%) |
| Dead | 103 (6.1%) | 0 (0%) | 62 (11.9%) | 87 (6.3%) | 0 (0%) | 34 (14.3%) |
| Missing | 97 (5.7%) | 114 (4.9%) | 23 (4.4%) | 64 (4.6%) | 99 (4.3%) | 9 (3.8%) |
| Hospitalization | ||||||
| Yes | 1,502 (88.5%) | 161 (6.9%) | 519 (100%) | 1,238 (89.3%) | 149 (6.5%) | 237 (100%) |
| No | 192 (11.3%) | 2,185 (93.1%) | 0 (0%) | 149 (10.7%) | 2,131 (93.5%) | 0 (0%) |
| Missing | 3 (0.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Intensive Care Treatment | ||||||
| Yes | 403 (23.7%) | 33 (1.4%) | 200 (38.5%) | 356 (25.7%) | 31 (1.4%) | 99 (41.8%) |
| No | 1,294 (76.3%) | 2,313 (98.6%) | 319 (61.5%) | 1,031 (74.3%) | 2,249 (98.6%) | 138 (58.2%) |
| Invasive ventilation | ||||||
| Yes | 153 (9.0%) | 18 (0.8%) | 111 (21.4%) | 128 (9.2%) | 18 (0.8%) | 60 (25.3%) |
| No | 1,522 (89.7%) | 2,328 (99.2%) | 327 (63.0%) | 1,245 (89.8%) | 2,262 (99.2%) | 131 (55.3%) |
| Missing | 22 (1.3%) | 0 (0%) | 81 (15.6%) | 14 (1.0%) | 0 (0%) | 46 (19.4%) |
| 3-month follow-up available | ||||||
| Yes | 968 (57.0%) | 2,346 (100%) | 158 (30.4%) | 859 (63.0%) | 2,280 (100%) | 103 (43.5%) |
| No/not yet | 729 (43.0%) | 0 (0%) | 361 (69.6%) | 528 (38.1%) | 0 (0%) | 134 (56.5%) |
| Any symptoms at 3-month follow-up (if 3-month follow-up available) | ||||||
| Yes | 305 (31.5%) | 900 (38.4%) | 43 (27.2%) | 280 (32.6%) | 874 (38.3%) | 36 (35.0%) |
| No | 663 (68.5%) | 862 (36.7%) | 115 (72.8%) | 579 (67.4%) | 847 (37.1%) | 67 (65.0%) |
| Missing | 0 (0%) | 584 (24.9%) | 0 (0%) | 0 (0%) | 559 (24.5%) | 0 (0%) |
| Ability to work at 3-month follow-up (if 3-month follow-up available) | ||||||
| Yes | 454 (46.9%) | 1,754 (74.8%) | 41 (26.0%) | 442 (51.5%) | 1,729 (75.8%) | 30 (29.1%) |
| No | 89 (9.2%) | 126 (5.4%) | 91 (57.6%) | 85 (10.0%) | 124 (5.4%) | 59 (57.3%) |
| Missing | 425 (43.9%) | 466 (19.9%) | 26 (16.5%) | 332 (38.7%) | 427 (18.7%) | 14 (13.6%) |
3-month follow-up obtained 10 to 14 weeks after day of first COVID-19 diagnosis (for POP retrospective documentation). SUEP = Cross-Sectoral Platform; POP = Population-Based Platform; HAP = High-Resolution Platform.